Louise Flanagan

A mutational hotspot that determines highly repeatable evolution can be built and broken by silent genetic changes

J. Stephen Horton, Louise Flanagan, Robert W. Jackson et al. · Nature Communications · 2021 · 46 citations · Full text

Life Sciences, Genetics, Microbiology +17

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial

Rakesh Popat, Sarah Brown, Louise Flanagan et al. · The Lancet Haematology · 2016 · 43 citations

Medicine, Hematology, Pharmacology +12

Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial

Sarah Brown, Andrew Hall, Hannah Buckley et al. · BMC Cancer · 2019 · 39 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

SELIMETRY—a multicentre I-131 dosimetry trial: a clinical perspective

Jonathan Wadsley, Rebecca Gregory, Glenn Flux et al. · British Journal of Radiology · 2017 · 32 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

MUK <i>nine</i> OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II study evaluating optimised combination of biological therapy in newly diagnosed high-risk multiple myeloma and plasma cell leukaemia

Sarah Brown, Debbie Sherratt, Samantha Hinsley et al. · BMJ Open · 2021 · 27 citations · Full text

Medicine, Hematology, Oncology +14